EU/3/08/590

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in June 2015 on request of the Sponsor.

On 5 December 2008, orphan designation (EU/3/08/590) was granted by the European Commission to AstraZeneca AB, Sweden, for 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate for the treatment of acute myeloid leukaemia.

 

Key facts

Active substance
2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate
Disease / condition
Treatment of acute myeloid leukaemia
Date of first decision
05/12/2008
Outcome
Withdrawn
EU designation number
EU/3/08/590

Sponsor's contact details

AstraZeneca AB
151 85 Södertälje
Sweden
Tel. +46 8 5532 6000
E-mail: kontakt@astrazeneca.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating